Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct commu
- PDF / 1,186,323 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 7 Downloads / 164 Views
RESEARCH ARTICLE
Open Access
Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct communityhealthcare outreach centres: the ANRS-SHS 154 CUBE study Ruxandra Calin1,2* , Véronique Massari2, Gilles Pialoux1,3, Nelly Reydellet4, Eve Plenel4, Carole Chauvin4,5, Marie Jauffret-Roustide5, Nesrine Day6, Georges Kreplak6, Anaenza Freire Maresca7,8, Nicolas Derche4, Sandra Louis9, Stanislas Pol10, Véronique Doré11, Christine Rouzioux4,12 and Pierre Chauvin2
Abstract Background: HIV, HBV and HCV infections continue to represent major health concerns, especially among key atrisk populations such as men who have sex with men (MSM), people who inject drugs (PWIDs), transgender women (TGW) and sex workers (SW). The objective of the ANRS-CUBE study was to evaluate the acceptability of a healthcare, community-based strategy offering a triple rapid HIV-HBV-HCV testing, and HBV vaccination, targeted at three priority groups (MSM, PWIDs and TGW/SWs), in three community centers, in the Paris area. Methods: This longitudinal multicentric non-randomized study included all adult volunteers attending one of the three specialized community centers in Paris, between July 2014 and December 2015. HIV, HBV and HCV status and acceptability of HBV vaccination were evaluated. Results: A total of 3662, MSM, 80 PWIDs and 72 TGW/SW were recruited in the three centers respectively. Acceptability of rapid tests was 98.5% in MSM and 14.9% in TGW/SWs, but could not be estimated in PWIDs since the number of users attending and the number of proposals were not recorded. User acceptability of HBV vaccination was weak, only 17.9% of the eligible MSM (neither vaccinated, nor infected) agreed to receive the first dose, 12.2% two doses, 5.9% had a complete vaccination. User acceptability of HBV vaccination was greater in PWIDs and TGW/SWs, but decreased for the last doses (66.7 and 53.3% respectively received a first dose, 24.4 and 26.7% a second dose and 6.7 and 0% a third dose). Fifty-three participants (49 MSM and 4 PWIDs) were discovered HIV positive, more than half with a recent infection. All but two HIV positive participants were linked to appropriate care in less than one month. (Continued on next page)
* Correspondence: [email protected] 1 Service de Maladies Infectieuses, Hôpital Tenon, Groupe Hospitalier Est, AP-HP, 4 rue de la Chine, 75970 Paris, Cedex 20, France 2 Inserm, IPLESP, ERES, Institut Pierre-Louis d’épidémiologie et de santé publique, Sorbonne Université, 75012 Paris, France Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this
Data Loading...
